Strides Pharma Trades Flat Despite USFDA Clearance

Shares of Strides Pharma Science Ltd are trading flat after touching a day’s high of Rs 889.90 on 5th February, even as the company announced that the US drug regulator had issued a Voluntary Action Indicated (VAI) status under its inspection closure report for the formulations facility of its US-based step-down wholly owned subsidiary.

The USFDA inspected Strides Pharma Inc.’s Chestnut Ridge facility in New York from 17th December 2025 to 23rd December 2025. The inspection covered current good manufacturing practices and pre-approval checks.

The inspection also included a review of the company’s drug–device combination capabilities. This was reflected in its recent filings in the nasal sprays segment.

At the end of the inspection, the USFDA issued a Form 483, to which the company submitted its response.

Based on this response, the USFDA classified the inspection outcome as Voluntary Action Indicated (VAI).

The establishment inspection report (EIR) confirmed that the inspection has been closed, according to the company.

The Chestnut Ridge facility serves the US market. It manufactures liquids, gels, hormones, modified-release products, and controlled substances. As a result, it supports both existing and upcoming launches.

At 12:10 PM, shares of Strides Pharma were trading 0.57% lower at Rs 861.55 on NSE.

Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!

The post Strides Pharma Trades Flat Despite USFDA Clearance appeared first on Equitypandit.